Multiple trials now demonstrate the potential for success and the safety of an attempt at treatment-free remission (TFR) in patients with sustained
deep molecular response to tyrosine kinase inhibitors (TKIs) [1,2,3]. We describe two patients who remain in treatment-free remission after achieving
undetectable BCR-ABL with ponatinib on the phase II PACE trial, despite being multiply resistant/intolerant to other agents or carrying the T315I mutation.
Download the article